Loading
A phase 3 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT04162210 by GlaxoSmithKline, with 325 participants enrolled, started 2020-04-02 and due to reach its primary completion in 2022-09-12. Interventions recorded: Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone). Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
325 enrolled.
95% CI 6.4 to 14.5; Figures from the ClinicalTrials.gov results section (first posted 2023-10-06), not from a publication · 95% CI 4.6 to 10.6
Source95% CI 19.4 to 33.2; Figures from the ClinicalTrials.gov results section (first posted 2023-10-06), not from a publication · 95% CI 16.0 to 29.3
Source95% CI 34.7 to 48.1; Figures from the ClinicalTrials.gov results section (first posted 2023-10-06), not from a publication · 95% CI 26.5 to 45.4
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)primary | Belantamab Mafodotin | 218 | 11.2 months | 1.03 (0.72 to 1.47) | 0.558 | link |
| Pomalidomide Plus Dexamethasone | 107 | 7 months | ||||
| Overall Survival (OS) | Belantamab Mafodotin | 218 | 24 months | 0.98 (0.73 to 1.3) | 0.440 | link |
| Pomalidomide Plus Dexamethasone | 107 | 22.9 months | ||||
| Overall Response Rate (ORR) | Belantamab Mafodotin | 218 | 41% | - | - | link |
| Pomalidomide Plus Dexamethasone | 107 | 36% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, Relapsed or refractory multiple myeloma, Multiple myeloma, Antibody-drug conjugate (ADC).
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, Relapsed or refractory multiple myeloma, Multiple myeloma, Antibody-drug conjugate (ADC).
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/